Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
108 hedge funds and large institutions have $148M invested in Paratek Pharmaceuticals, Inc. in 2020 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 33 increasing their positions, 30 reducing their positions, and 15 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
74% more call options, than puts
Call options by funds: $2.11M | Put options by funds: $1.21M
67% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 15
22% more capital invested
Capital invested by funds: $121M → $148M (+$27.2M)
10% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 30
8% more funds holding
Funds holding: 100 → 108 (+8)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$2.45M |
| 2 |
Two Sigma Advisers
New York
|
+$1.84M |
| 3 |
Renaissance Technologies
New York
|
+$1.29M |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
+$1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$908K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$2.57M |
| 2 |
D.E. Shaw & Co
New York
|
-$1.29M |
| 3 |
WIC
Water Island Capital
New York
|
-$862K |
| 4 |
Invesco
Atlanta,
Georgia
|
-$771K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$660K |
PRTK Hedge Fund Activity: Q4 2020 in Review
108 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2020, worth a combined $148M — up 22% from $121M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PRTK positions and 15 closed out — a net gain of 10 holders — while 33 added to existing stakes and 30 trimmed.
The largest buyer was BlackRock, adding an estimated $2.45M. The largest seller was Morgan Stanley, cutting an estimated $2.57M.
- 108 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2020, up from 100 in Q3 2020.
- Funds reported $148M of Paratek Pharmaceuticals, Inc. stock for Q4 2020, up 22% quarter-over-quarter.
- 25 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2020 and 15 closed out, a net change of +10 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2020 was BlackRock, an estimated $2.45M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2020 was Morgan Stanley, an estimated $2.57M sold.
Based on aggregated 13F filings for Q4 2020.